Anti-cancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expressing COX-2 oncoprotein.
Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with antitumor and antiangiogenic activities. To investigate the effects of celecoxib on nasopharyngeal carcinoma (NPC), HNE-1 cells were treated with celecoxib at various concentrations. MTT assay, migration assay and invasion assay were performed to observe the inhibitory activity of celecoxib on HNE-1 cells. Additionally, VEGF-A expression and radiation survival of NPC cell were also examined after treatment with celecoxib. Celecoxib treatment presented an anti-proliferation function in a time and dose-dependent manner on HNE-1 cells which highly express COX-2 protein. Celecoxib also displayed an obvious inhibitory activity on invasive capacity of NPC cells. Moreover, the celecoxib's effects to suppress VEGF-A expression and enhance radiosensitivity were detected in HNE-1 cells. These findings implicate that application of celecoxib may be an effective strategy for NPC therapy.
Chen
Jiongyu
J
Tumor Research Lab, Cancer Hospital of Shantou University Medical College, 515041, Shantou, People's Republic of China.
Ran
Yonggang
Y
Hong
Chaoqun
C
Chen
Zhijian
Z
You
Yanjie
Y
Int J Cancer. 2004 Nov 20;112(4):628-35
15382043
Ann Oncol. 2006 Nov;17(11):1625-30
17008411
Clin Cancer Res. 2006 Aug 15;12(16):4989-99
16914589
Int J Mol Med. 2005 Dec;16(6):993-1002
16273277
Surgeon. 2009 Jun;7(3):174-80
19580182
Mol Carcinog. 2007 Nov;46(11):912-23
17427962
J Gastroenterol Hepatol. 2009 Mar;24(3):480-7
18823436
Int J Clin Pract. 2008 Mar;62(3):444-9
18194278
Ann N Y Acad Sci. 2009 Aug;1171:635-41
19723114
Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):369-75
14751505
Biomed Pharmacother. 2005 Oct;59 Suppl 2:S268-71
16507390
Autophagy. 2010 Feb;6(2):256-69
20104024
J Gastrointest Cancer. 2007;38(2-4):78-82
19031117
Inflammopharmacology. 2009 Apr;17(2):55-67
19340409
Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):111-7
17482376
Clin Cancer Res. 2005 Nov 15;11(22):8213-21
16299255
Cancer Metastasis Rev. 2007 Dec;26(3-4):525-34
17763971
Mini Rev Med Chem. 2008 Jan;8(1):73-90
18220987
Oral Oncol. 2005 Oct;41(9):903-8
16054423
Neoplasma. 2008;55(2):122-6
18237249
J Clin Pathol. 2005 May;58(5):535-8
15858127
Recent Pat Anticancer Drug Discov. 2009 Jun;4(2):157-63
19519538
Int J Radiat Biol. 2007 Oct;83(10):677-85
17729162
Nat Med. 2003 Jun;9(6):669-76
12778165
Head Neck. 2005 Jun;27(6):503-12
15772955
Invest Ophthalmol Vis Sci. 1998 Mar;39(3):581-91
9501870
Cytotechnology. 2008 Feb;56(2):97-104
19002847
Acta Pharmacol Sin. 2004 Jul;25(7):943-9
15210070
J Cell Physiol. 2002 Mar;190(3):279-86
11857443
Invest New Drugs. 2007 Apr;25(2):123-9
17053988
J Clin Oncol. 2009 Oct 20;27(30):4986-93
19720908
Am J Med Sci. 2009 Aug;338(2):96-106
19680014